Open AccessOne‐year experience in patients treated with auranofin following completion of a parallel, controlled trial comparing auranofin, gold sodium thiomalate, and placebo
Author(s) -
James Williams H.,
Dahl Stephen L.,
Ward John R.,
Karg Miki,
Willkens Robert F.,
Meenan Robert F.,
AltzSmith Mary,
Clegg Daniel O.,
Mikkelsen William M.,
Kay Donald R.,
Weinstein Arthur,
Guttadauria Maria,
Paulus Harold E.,
Kaplan Stanley B.
Publication year - 1988
Publication title -
arthritis & rheumatism
Language(s) - English
Resource type - Journals
eISSN - 1529-0131
pISSN - 0004-3591
DOI - 10.1002/art.1780310102
Subject(s) - auranofin , gold sodium thiomalate , medicine , placebo , open label , double blind , gastroenterology , clinical trial , rheumatoid arthritis , alternative medicine , pathology
Following a 21‐week double‐blind trial that compared the effects of treatment with auranofin (AUR), gold sodium thiomalate, and placebo in 193 patients, 147 patients entered a 1‐year, open‐label study of treatment with AUR (6 mg/day). Results of this open‐label study suggest that AUR has a long‐term use profile similar to that of other slow‐acting antirheumatic drugs. AUR appears to be capable of sustaining an initial response to gold sodium thiomalate. The withdrawal rate remains relatively high: Nearly half of the study patients had discontinued AUR by the end of 1 year.